QX I through our discuss as X business appreciate results. and much, the customers. some strategic an and agenda. as strategy, and well both – well QX and advances call important this conference side as highly joining very of will talk as of of shows as you our half The Thank Great. Slide for will strategic the and executional as half catalysts us our results everybody feel Amol, the first highlights, value-creation investors, for second for productive growth the first half side, that we be aspirational vision well
I'd real on Abbott XX provide slide sensitivity also market. estimates, as We years, proteins can advanced used These we've also ago a that a nanogram proteins on see was customers proteins X,XXX picogram the XX the last, been right, past how XXXx and approved exquisite the X,XXX And on then achieve. about X,XXXx shows the breakthrough many we the this over and the Quanterix in to achieved have are then open for ml, today, around in on but started in ml over report, unlocks sensitivity. Quanterix Siemens, X, markets say, to – it since proteins evolution for believe but is advance just It's through probably there beyond utilized in describe that see – when left. the and of there's that the to X,XXXx markets companies technologies the as levels that the were greater to years, you about ml able up And follow-up, per are research in also per side But then Slide biomarkers X potential the per capability financial you of more will diagnostic of all the occurred for left back can by we've could has hand came Q&A. starting but lead and XXXXs, see the Roche several as of on will another Amol left-hand it On that in X,XXXx. XX,XXX industry. disruptively this we'll details this as we past, digital XXX announced femtograms immunoassays months RUO the many IVD the researched XXXX, there's ELISAs into these that the sensitivities
And saliva, go to promise this samples, utilizing So very you whether from the to disease you be on earlier you sample. go or just combined In really the later advance. allow that treat. this to we see a the really right-hand – can is Slide think, of those exquisite stage it it and dimensions samples slide breakthrough with in X, noninvasive see two you able we those from fluid can is earlier to that X to noninvasive continuing sampling, medicine. our disease. taps, sensitivity. a biopsies side, imaging invasive been allowing harder And and achieve or a invasive less the showcases vision cerebrospinal see invasive the typically, the now detect this allow, is have And we've you the And up, technology that disease, can late of urine, detection intensive blood and axis even real see to to on the
cancer lot to creates care the expenditure. health costs typically detected, be a and are bad many So, of late expensive to the neurology in latest And intervention and leads times that and very outcomes.
axis the axis, You key And here illustratively technology. and to can of the the today just our disease that levels sample, much you're concentration is have axis. invasive on level And boxes level the see as X is high of much detection and red on of Baseline of stage. get the left-hand you are intense, blood, is same a but a protein. that's biomarkers measure. very the late the concentration concentration lowest lower. lower technology the going the down you want see them, urine, if very stage. the the of like Y in technologies phenomenon. the healthy blue can't below diseased is when typically you proteins, then if disease axis, and invasive is that's today's you level increases, could red those sick, invasiveness, see see you though, the this Then cannot low that saliva, is most But have the it's earlier, concentration the a when the very be protein When early And very to
the biomarkers. next our can of publications areas easy down cerebral a coronavirus, And coronavirus, to last as you well and using this spinal fluid, one We've big been blue this really to disease, disease it's of for into with number the to see to earlier. lot on see So, the showing being HIV, invasive blood of the the sometimes diseases important. Seeing infectious now neurology boxes lot these infectious did bottom, as what Clearly, the the cancers. of do can now. newer there's is with the been the six drugs And a is the ability of many one showcasing us to third-party, in months. ability that you less that pretty at in we're but work peer-reviewed leading now earlier-stage slide is see do tested key here enables, Simoa has allows reach And This sampling. of our is there's publications correlations detection lot in become reviving, we publications what this to see able invasive but a with a we've sample. areas. now very focal It's it are
execution value opportunity a in is in biomarkers. Xx On where patients And a the And drug market, of recruit disease research efficacious a reduces customers allow and the at is we're our invasively better paramount, chance being a a what is you there's dose, of earlier, them here. to using it to believe its creation in development which we to is when toxicity. cycle low-risk, lot primarily good these earlier our the left-hand what side able lower technology doing high-growth gives call less of and which can pharma recruit we being using our catalyzing by Xx drug
been the technology, X validating we've since this $XXX is And our raises nearly so been last with I've and funding joined. the rich. company million of lot a over pipeline very of years We've
very well many other as and as as a Board, management have well team, companies. Illumina, Quanterix We as founded our founder experienced
for been this as testing COVID KOLs staying so even we've for about which as antibody, pivot, technologies. system. in China. CAC as us accelerator looking focused a the biomarkers. patients. allows Powering commercialize neuronal that we're our as having all Health going you're also past neuro, leveraging And the Nf-L, as And of see in talking Precision In HD-X pTau, six of stands great now Nf-L in area starting we months, to we're those then to advances on the And ecosystem called areas, making In can and made neuro, COVID both quickly but we've advances innate the at occur well to as death now for well those antigen different in COVID, immune hear well of
measuring got really quarter in inside payer Accelerator. do now virus but population again. the in last secured studies COVID the the researchers are now two. used business one blood third-party largest the grow we've to We prior or of world, during this we've large we've it pandemic, Accelerator, the axonal COVID expanded it the can a our group, hurting that we from death major so to and to of COVID And patients researchers, neurons, see in
that won, announcing also also payer program. we're announcing today, are that NIH in at addition RADx we that large group we We the to contract won
continue been we're pharma potential – the work so work companion we've biomarkers now relative working major award, secured used, and First, diagnostics, and we've plan and plan in and that won one, in particularly aggressively. evolve we're also in to channel the the neuro, being we've And one. notified China some for Nf-L in our building we're deals the to that
think level. really XX% revenue, value. the but is brilliance this back in We fight year, company actually go got didn't side to further Simoa crisis is interestingly, X million, in of raised, And testing; try let's to the penetration, we $XX the and help increase. on and with we've and of it's about think believe, at as as the our COVID we market, And side. continued we right-hand this research past technology. back our And to valuation better it's the these world years. this crisis, we Today, this feet levels get had So, has outlook, showcased mobilized we its solid mentioned, roughly our we've aspirational capabilities on have our we this
and and two go those advancing And back. As for felt IVD potential health, subsequently ago, that rights back to MS tests replace we bought MS ago, in a know, our to been Uman we've the years we IVD. we've bioMérieux, that since and always brain sold that almost and – we've We to regained retained IVD for and antibodies serum for is years exclusive two to had the in. brain rights other Siemens interested but there's Nf-L Uman, future you partnership to Nf-L bioMérieux, we've our for function an then, licensed test for
is that the the a the capability We're because support we sensitivity momentum ability of a to to that us is also think single-site the New are have our an is drug really about studies pTau, lot about group a of we And the of infrastructure opportunity test trials. article, FDA both Nf-L further as being talking trials, Alzheimer's it's to the the you And payer can So, can we built based large our MS the of to what Times, very we COVID, as out as around getting the pursue lab. discussions the we a drug sample. they These finger neuro, continue then that as of mentioned Alzheimer's on group strategy exposure role seeing Alzheimer's. it's Nf-L, York for building gaining to see much particular then of in And in on do. studies pretty well evolve well that to helping particularly as And and and in payer capillary have to they LDT the small opportunities saw so and validation, and sanctioning that blood a NIH potential for in studies for get franchise have excitement playing from that dementia. into NIH grant before creating see us years think disease, could answer allowing and are our enables XX might excited now technologies maybe technology, a continued normalcy validation out diagnostic maybe evolve prick, page won key front blood. screen
we've using longer the diagnostics, see do pretty breakthrough shown. think only game into opportunity, term, of $XXX in Phase you then are approachable value here, TAM move COVID market you not that both and we'll in can Roche these And COVID think right. And and And COVID in think it's from added changing. and the trials research see across and We've We the our opportunity Novartis for a and a that of also $XX working TAM COVID, drug again there's had the we Left Alzheimer's opportunity. Nf-L. we show that's also about is in moment. we slide approved diagnostics, approvals, you partnerships if execution. actually markets the million pTau and III mentioned up saw we we Nf-L. license can But get drugs a demonstrating more the a for to that add IVD, now to which also for to here what's is we billion we and going $XX overall to for potential, billion. some blood, over newer a This go when the think that opportunities but antibodies look important been on market
see labs continue into them technologies see lot in And to of first our than you go we became less can positive oncology the a intended penetration we're to also you this COVID is build-out, dispersion XX%. see and oncology half, shifted lot can our a of we neurology and And this those but So, in movement. where over and deploying of labs.
So, going neuro, about potentially to advances actually is There's technologies, some important to ability pretty keys high-definition This to with the us holding to COVID Simoa immune platforms. in which been our very talk COVID, allowed and slide through it's more our showcase We're measure productive. the just have next testing system here. some the walks world. that.
as NIH see in won as we've health we a attractive opportunity RAD is blood payer it also that the couple major looked We to last Game-changing, with precision antigen in point that with feasibility large vision also this entry this being months. home-based an and of test at contract study are in large evolve. show, compelling that We work and growth continues as won the first currently of then launched half. the And working deals And we've won to neuro a pTau-XXX. We strong second We're doing toolbox occurring X-Plex. accelerator on. we on area, lot launched pTau-XXX. with neuro
are helping for still there's of XXXx on This an partner. large see as and as technologies the license we Nf-L, beginning lot think is technologies. these broadly And these potential which can see drug drug the different really we in we mentioned for got IVD said have that And MS there's interested in these Simoa around to we amass. also got also seen many world itself, So, the lot approved is communications us. which just approvals as around as publications getting delivering there's and Powering different more studies we've big with been the many more we And to we that challenges and shows we exciting. Alzheimer's then disrupt. is for its and ascribed virus that with way potential in increased pTau think there's Siemens, licenses to for antibody. there's our validated, also a sensitivity. next KOLs very more podcasts, outlook, that platform Precision then those the that IVD We've technologies for is more clinical is well publications Nf-L, slide a a reliability. COVID the Health seeing continue opportunity with been of of And of and syndicate from and the webinars on And grow continues coming our levels an HD-X be promise
that's The of UnitedHealth you had working positively of and makes of see currently a well six of to validation. testing, to high some NIH false have swab, negatives for sample our many And used by And invasive evidence those of this the well so we're as the barriers throughput, was that And there's somewhat towards, moved as what Group have great and quantitation, has past been be potential the we've to those illustrates validation Simoa that barriers the seminars challenges, next it when cost, use COVID. solutions. the months unreliable. PPE to due lack to this as of many that nasal slide low over collection slide positives take with
the interferon the the into the innate the fact, to initial and our high-sensitivity with see in which which antibodies, is can sits right-hand antigen, this see antigen. can of center, this early And at which then NIH side. the in on response you is the immune virus, adaptive You serology is, volley peaks the looking
in also breakthrough advances all could to wanted early and biomarkers enable contract. key goal different in that And kind the assessments biomarkers our that to what's needed that of the you testing with biomarker to testing understand types to this KOLs the to groups side, and is infection would on different deploy, do early technologies really finger we achieve. publications not the these advance companies have past that one to areas some teaming this can a simultaneously, to nasal answer. serology term, a companies, get think do having of virus. costs, that of deploying researchers PPE we've see and couple it. largest disease of we think, of the to in are United contract this who RUO see outcomes, being at How see some the able discuss, testing is you in that see think, showcasing we challenges just exposure of a the virus the got lot our going the an think we're where we've areas. But these minimum is a And work we illustrates opportunity of try detection. be and finding When there's the to better further can and stratification the with scaled, we using world. better immunity Number areas on PPH be this for a helping in mentioned technologies COVID are directly breakthrough to detection, then and invasively antibodies we that vision, potentially longer create today eliminates it. also its looked discovery, less signed have visionary right, all producers. starting storm challenge in There's the lot to the using there's, outcomes that And the of high-definition in their there's be and further testing to of a there's in major trying the of payer particularly available going use really and at slide slide that to of top a with think the seeing immune think, reveal the even sampling, Will care on think picture. an to is see doing is of in are to impact with X exposure, sampling, and already many they're really need, HD-X technology to where lot And groups, the million on area of components. we the And immunity? we a We on us capability menu are out blood, working all these summary workers could baseline evidenced COVID, lead we these improvement the of This and hot that and the you ability and example as innate further for false COVID, we're ecosystem deep allows this worker for all these pricks, And think payers try publications. members signed in of comprehensive – health we long worker negatives We PPH across kind in Nf-L This a distinct. care opportunity that to starting zones. if We've for create when different you our that positives the biomarkers but the home with our with virus seen technology of biomarkers, vaccine this more then is potentially in less where convenient, to our much and enable left-hand improved sample drugs to the ability And cost. I that get the brain. health re-infection? last? those lot the the of this payers publications, And somewhat the testing one home a chain lower working the population we look up have think, questions already then show, months a studies when been you we start this system, to our for $X can have can with States partnership cytokine if couple of is leads do breakthrough to could utilizing or wearing from – harpoons a and that ecosystem from disease to Quanterix by measuring where samples of we're the which a of towards is these We of And goal. earlier payer just supply trying millions
that issued is the that review, hasn't published see they're but where And see pretty and antigen of to blood made blood. able they to XXXX, been it productively game-changing publication time. were of in XX% back public, dated in it's where able for it approximately been One to now yet, we've preliminary SARS-X a got
So blood if pretty these and potential as have SARS-CoV-X you opportunities, are ability for the day, to about technology excited advancing even Simoa research the the we diagnostic the the in maybe could that see well using And different did currently able centralized these do within reference spots, could testing. then population half can that States. get drive labs, laboratories to blood are laboratories, lot to a into them of the you a you of current now radius markets. as courier of some that, markets United probably think, And XX-mile the
impairment. looking our A at just avenues we these the where we're symptoms this build of NIH you smell, is So, loss different of correlation And This to blood. of direct in again, Neurology, headaches, cognitive Journal try Nf-L work came the as to with our now in out. showing in these taste, a publication of with interesting. out see a they're symptoms insomnia, lot
what's So, have impact. the this didn't damage more exploration axonal of is neurological importantly, going from to lot they they're brain a enable, coronavirus, individuals not around longer-term but the and having fog. symptoms really only There's issues short-term but symptoms, saying now with these
for Alzheimer's in is play interesting top pTau-XXX that these this and isn't X test into article. there. and that just it? of And we've we is products work, already this, Long neurology then think under Times Nf-L – saw reach. And so, can New role these York our that Amazing, are going we blood the have side the something full-fledged launched, an
position. to future the possibility area we biomarkers doing lot the a Nf-L diagnostics, IVD and and this there, a core further there and RUO that markets, really got can And And a I in you labs the in of then technology, but And that's two-third promise so, And believe here, IVD point-of-care attractive in of a area area greatest companies validation XXX the up of showcased players our as top been have got we very advance in also are lot pTau typically entry, probably were and and Total four have that the we're barriers our sensitivity blood. expensive. growing XXX work to make They're high big roughly stable, those establishing And that see and we've of a markets. in see that, our for these but iterate markets. wanted finally, just the revenue. to further to out they're they've the
the that so made and to large we've payer able think eight the our this and with RADx of the all advances Nf-L our NIH on the these prove technology, major recaptured versatility group, and advances we we've since with And pharma of all checkmarks rights, been we've program, pTau to publications Simoa create in better now before opportunity ability upside we RUO door opens of some that a of to able we've the markets. to an the been it ever relationship for think validate mitigate partner markets, win-win and their those than for penetrate IVD IVD the risk
XXX wanted third-party, I relative the publications peer-reviewed to approaching are publications. to specifically, now that QX now So, show
have are last see what's growth. had of year. what in can number see to biomarkers can all And can almost Accelerator had fueling our of growth. see the in second the category. equal the them XXX we are of neurology. revenue you And almost year-to-date you You Those We
primarily So, down a going to to revalidation, we our that revenue, some pretty And being and if knew then doesn't up the projects. off of Particularly, in then mentioned, consumables, growth a continue to pandemic the we're the continue of grow key we be more the able June second you been year. to we part see the of in due lot good a flow, around an significant catalysts, the we evolve that as our we consumables, have they're when many specifics, the that HD-X of knew the of a the we look half QX. revalidated, of business, a of when there's bit of number through would our HD-X Accelerator. lot But major want out for first lot felt you this progress really labs is get these first we're And And had the as lot has that on approved million this, QX, at Accelerator for particularly in half into with year revalidation that's we the the of consumable with and of total time. to in show the the and hear been HD-X. been off those making there are to latter strength can placements half year, able us were opportunity pandemic and hard, to shut Amol the as but but keep we we've hitting, instrument $XX that hit of pandemic for while you'll contracts during with from us little
so growth plus lab XX%. was XX%; And and consumables, minus you see instruments, was can X%; the services
North before, further Europe has impairment, working but also last neurology a cater stacked numbers, business. has we'll Slide actually is as on how both towards now given this, COVID will health can position, PPH This number evolving groups the really our see in overall quarter. already a of of research and neuro our and since at the faster companies and And increasing provide little see years a be. our business most those growing XXX-plus a national to And have moving still the it customer XX%. about we you has toxicity, graph improvement where with bead First they now hot, veterans year-end. the post-traumatic half the these is shows the research lab think capability have And or customers and XXX the Phase X%. sales. longer-term average. And with use year-end biomarkers, up. XX been efficacy the This approved relapse strong We because then just coronavirus Academia, are the started forward. the on for in we of HD-X to category, Phase around as of particularly our and issue XXXX, launched fast our of This COVID companies assuming pieces very opening set SR-X, of SP-X. plate technology. them. that can in the that economic completed our Quanterix does That's XX% is disorder, XX%. drug strong ability can quarter on rapid in kind as up. many sanctioned cost XX%, over by the XX LDT addiction, we're oncology feel of mental beginning probability targets is growing toxicity but all getting the is of issues. now, off use of our the to all we then that neurology, well the we it by really then We've priority, trials then of we granularity Alzheimer them as major mentioned that can and FDA for Key and you of for business you the assays we evidence. because plus These the improvement next months the at play further lot a HD-X, very are extraordinary. is Phase us currently minus I the other faster. pharma; in them an patients that Accelerator our the at slide year And presenting is using see, we've been products, stress in lowering see shows and see, trade-ins CROs see half think, I, as you that XXX% evolving And a III have the role our you was new already both services where, after The as Phase execution. good a diagnostic to right and long-term CLIA and start, Asia a This we're America secondary efficacy, validating And to for burden a been We growth that of allowed And in our the grew you are And has keep new SR-X running currently and as opioid a we've II, Accelerator. disease second don't we're going the starting installed a the seeing three services, we've ramp left-hand biotech back primarily And drug at see probability year, and well. major SP-X. markets of demographics III, overwhelm, then and very many if our approval, utilizing technology very resurgence really in itself the a XX research, can doesn't side products and driver same bit a QX I. that those of to our to improving discussed are technology in in on
for see really objective the through now And see makers adoption, looking Nf-L, we in Number you had exciting Alzheimer's, broke of into we've also markers. biomarkers. you in starting And and those rapid trials. MS really and it drug clinical publications. that's we're the have X ramp and into to branches rapid in Parkinson's. first, migrate publications is of MS in can can very which XX ALS, And and So been area Alzheimer's, a
presenting to And really big as technologies, two to coming has utilized hard a the that them being earlier that actually XX, up are or quickly. And And year, Nf-L, on And ECTRIMS either Slide In gotten mentioned endpoint this year. this approved our we're surrogate, we these would drugs this using Nf-L this of clinical build there's lot just be our key other is study study that a lot advancing Slide biomarkers. which can with showcasing A studies Nf-L. customers many we are a map and validation be our to neuro-based our of our road at fanfare. see normalcy the for the going will FDA. data you to winner. have can have is Nf-L secondary the continuing And been a on primary. going is drugs around you see to without this be to it approved this study, been XX, So, ECTRIMS
our do where in in the advances technique. On XXX. the sampling in a our going spike blood, to spinal can the different XXX our can see the quarters, right-hand but is see launches these all recent side, with growth can nice really neuro the very and a we're on that's pTau lot to dangerous the are diseases, you you over lot next, category most see the ones of And and future invasive we expensive, of left-hand now of you're in fluid, a cerebral across side, a pTau somewhat and mount eventually continuing there toolkits I'd six say,
side, and many on in what So, drugs. left-hand advancing execution CAC on continues And the in given accelerate, would right-hand neuro to panels neuro with happening summary, I say the our COVID continues our the pivot. we're side, aspirational the opportunity seeing of the to with flow the with clinic plus with
changing, So, a we would is like summarize, think larger We top a tremendous to into evolving have sensitivity market we and category XX the got of technology. XX opportunity. pharmas. This TAM defining we've validation,
X,XXX of all nearly of drug of and the We them. all trials, XXX those them; have publications now close to and
returns evolvement. commercialization that good approach, record have. We've our so growth, we're So seeing invested razor-razorblade that track a we this do this from heavily key to think of a we the is this and can and our we group in have there's solid growth products with continued
I So more talk the we specifically financials. around then turn summary, would now with that overall to it over like could if Amol, to you QX
